Sotorasib: First Approval | SpringerLink
Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand? | Journal of Clinical Oncology
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM
Sotorasib Impresses in Advanced Pancreatic Cancer | MedPage Today
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC - ILCN.org (ILCN/WCLC)
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
Similarities and differences among sotorasib and adagrasib (direct KRAS... | Download Scientific Diagram
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes | npj Precision Oncology
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial - The Lancet Oncology
Sotorasib Tablets
Stephen V Liu, MD on Twitter: "#ESMO20 Overall, sotorasib showing clear efficacy (RR 32.2%, DOR 10.9m, PFS 6.3m) and excellent safety profile. Would have a clear role today in salvage setting. Good
![Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate | springermedizin.de](https://media.springernature.com/lw150/springer-static/cover/journal/280/90/4.jpg?as=jpg "Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate | springermedizin.de")
Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate | springermedizin.de
Why did FDA ask Amgen to add low-dose trial of Lumakras? < Pharma < Article - KBR
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
Stephen V Liu, MD on Twitter: "#ESMO20 CodeBreak100 is a phase I escalation/expansion trial of sotorasib monotherapy in KRAS G12C tumors. Primary endpoint was safety. Escalation established preferred dose of 960mg qday. #
Dose Finding in Oncology: What is Impeding Coming of Age? | SpringerLink
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial | MD Anderson Cancer Center
Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration - ILCN.org (ILCN/WCLC)
Dr. Antonio Calles 🫁🚭 on Twitter: "💥 Sotorasib vs docetaxel for previously treated NSCLC with KRAS G12C mutation: CodeBreak200 phase IlI study 😕 ORR 28.1% 😕 PFS 5.6 months (delta 1.1 month)
LUMYKRAS - Amgen.de
LUMAKRAS® Once Daily Oral Therapy | LUMAKRAS® (sotorasib)
Data presented at ESMO strengthens concern that the labeled dose of sotorasib is not optimal - The Cancer Letter
